The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...
The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...
GlobalData on MSN21h
How decentralisation can fill the gaps in Alzheimer’s researchAlzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
Biogen (BIIB) is down more than -1% after Needham downgraded ... the stock to underperform from hold with a price target of $164. AECOM (ACM), BellRing Brands Inc (BRBR), Bit Digital Inc (BTBT), ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Don't Miss our ...
HCW Biologics entered into License, Research and Co-Development Agreement HCW Biologics to receive upfront payment of $7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback